WASHINGTON DC—Patients with metastatic breast cancer who are HER-2 positive could potentially be treated with the anti-HER-2 conjugated drug, trastuzumab-emtansine (T-DM1), alone — without needing to add chemotherapy. This prediction was made at the American Association for Cancer Research annual conference by Dr Jose Baselga Physician in Chief at New York’s Memorial Sloan-Kettering Cancer Center on the basis of data the EMILIA study (which led to the approval of this agent in the USA in 2013). He gave Peter Goodwin details about the effectiveness of this new agent in the presence of PI-3 kinase mutations.
You may also like...
Stage IV Pancreatic Islet Cell Tumors: Sunitinib Monotherapy Increased Progression Free Survival 28 Jul, 2009 UK TACT2 trial confirms chemotherapy is highly effective in early beast cancer 18 Dec, 2012 Enzalutamide in metastatic castration resistant prostate cancer: over 75s benefit too 24 Mar, 2013 Audio Journal of Oncology – June 7th 2006, from the ASCO Annual Meeting in Atlanta, June 2-6 6 Jun, 2006
- Previous story Two-step immunotherapy brings promise in advanced ovarian cancer
- Next story Chimeric antigen receptor T-cell therapy rescues kids with relapsing acute lymphoblastic leukaemia
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014